Imunon (IMNN) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company developing non-viral DNA technology for immunotherapy and vaccines targeting solid tumors and infectious diseases.

• Lead program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer, completed Phase II and moving to Phase III with FDA-aligned protocol.

• Additional pipeline includes a COVID-19 booster vaccine (IMNN-101) in first-in-human studies.

• Recent developments include a warrant exchange representing 19.98% of outstanding shares as of May 2025.

Financial performance and metrics

• Net loss of $4.1 million for Q1 2025 and $18.6 million for FY 2024; cumulative net losses of approximately $411 million as of March 31, 2025.

• Cash and cash equivalents of $2.9 million as of March 31, 2025, down from $5.9 million at year-end 2024.

• Substantial doubt exists regarding ability to continue as a going concern, as noted by independent auditor.

Use of proceeds and capital allocation

• Estimated net proceeds of $7.2 million if maximum securities are sold, with lower proceeds possible due to best-efforts structure.

• Proceeds intended for general corporate purposes, clinical development of IMNN-001, capital expenditures, and working capital.

• Management has broad discretion over use of funds.